Going Through Changes: Surface IgM Levels During CLL Therapy With Ibrutinib

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3725
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Ibrutinib Therapy Releases Leukemic Surface IgM From Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Clinical Cancer Research
Cancer ResearchOncology
2018English

Going Through Changes

European Journal of Information Systems
Information SystemsManagementManagement Information SystemsLibraryInformation Sciences
2018English

First-Line Ibrutinib Confirmed for CLL

Cancer Discovery
Oncology
2018English

Significant Weight Gain in CLL Patients Treated With Ibrutinib: A Potentially Deleterious Consequence of Therapy

American Journal of Hematology
Hematology
2019English

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Letter

Clinical Cancer Research
Cancer ResearchOncology
2016English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

American Journal of Hematology
Hematology
2018English

A Complex Case of Ibrutinib Treatment for a CLL Patient on Haemodialysis

British Journal of Haematology
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy